Journals / Osmangazi Tıp Dergisi / 2020 / Cilt: 42 - Sayı: 4

Therapeutic potential of morus nigra on 5-fluorouracil-induced gastrointestinal mucositis in rats

Morus Nigra'nın sıçanlarda 5-florourasil ile oluşturulmuş gastrointestinal mukozite karşı olası tedavi ediciliği

Pages
363–372
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results of the present study suggest that, though partly, MN-1 extract in particular may have biochemically and histologically positive effects against experimental mucositis induced by 5-FU in rats.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To investigate the therapeutic potential of Morus Nigra on the mucositis of digestive system induced via 5-fluorouracil in rats.
📊
Key Findings & Data:A total of 26 rats were divided into 4 groups as control (C), mucositis (M), Morus nigra extract-1(MN-1) and Morus nigra extract-2 (MN-2).
💡
Conclusion & Impact:Results of the present study suggest that, though partly, MN-1 extract in particular may have biochemically and histologically positive effects against experimental mucositis induced by 5-FU in rats.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Mukozit · Sıçan · Morus nigra

Abstract

To investigate the therapeutic potential of Morus Nigra on the mucositis of digestive system induced via 5-fluorouracil in rats. A total of 26 rats were divided into 4 groups as control (C), mucositis (M), Morus nigra extract-1(MN-1) and Morus nigra extract-2 (MN-2). Mucositis was induced by intraperitoneal injection of 60 mg/kg 5-fluorouracil (5-FU). The antioxidant enzyme levels in blood samples were analysed by ELISA. Histological analysis and immunohistochemical staining for NF-kB and TNF-α were done. Increased oxidative markers were found in mucositis group and increased antioxidative status was found in MN-1 and MN-2 groups. All histochemical analyses suggested that 5-FU causes intestinal degeneration; the MN-1 extract reduced this degeneration but did not completely treat it. The therapeutic potential of MN-2 extract was lower than the MN-1. Results of the present study suggest that, though partly, MN-1 extract in particular may have biochemically and histologically positive effects against experimental mucositis induced by 5-FU in rats.

Özet

Bu çalışmanın amacı sıçan gastrointestinal mukozasında 5-florourasil ile oluşturulmuş mukozit üzerine Morus nigra ekstresinin olası tedavi edici etkisini araştırmaktır.Toplam 26 adet sıçan eşit olarak kontrol, mukozit, mukozit+morus nigra ekstre 1 (MN-1) ve mukozit + morus nigra ekstre 2 (MN-2) olarak bölünmüştür. Mukozit sıçanlarda 60 mg/kg 5-fluorourasilin (5-FU) intraperitoneal olarak enjeksiyonuyla oluşturulmuştur. ELISA ile kandaki oksidan ve antioksidan seviyeleri ölçüldü. Histokimyasal ve immunohistokimyasal boyamalar (NF-kB ve TNF-α antikorları için) yapıldı. Mukozit grubunda artmış oksidatif stres belirteçleri görülürken Morus nigra ekstresi verilen gruplarda antioksidan belirteçlerin arttığı saptandı. Histokimyasal olarak 5-FU'nun mukozit oluşturduğu ve MN-1 ekstresinin tam olarak olmasa da tedavi edici olduğu gösterildi. MN-1 ekstresi MN-2 ekstresine göre daha iyi bir tedavi edici ajan olduğu belirlendi. Sonuç olarak bu çalışmada 5-FU ile oluşturulmuş mukozite karşı MN-1 ekstresinin kısmi olarak tedavi edici olduğu biyokimyasal ve histopatolojik olarak gösterildi.

🔖

Cite This Article

YİĞİTASLAN, S., ÖZKAHRAMAN, A., ACİKGOZ, A., ALPARSLAN, G. B., TOPRAK, C., GÖGER, F., ŞAHİN, E. (2020). Therapeutic potential of morus nigra on 5-fluorouracil-induced gastrointestinal mucositis in rats. Osmangazi Tıp Dergisi, Cilt: 42 - Sayı: 4, 363–372. https://ajindex.com/articles/287895

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Alterio D, Jereczek-Fossa BA, Piperno G, Laudati A, Ferrari AM, Giugliano G, et al. Oral cavity overinfection during non surgical cancer therapies: Review of the literature. International Journal of Clinical Dentistry. 2008:123
  2. Lalla R, Bowen J, Barasch A, Elting L, Epstein J, Keefe D, et al. Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453-61
  3. Silverman Jr S. Diagnosis and management of oral mucositis. The journal of supportive oncology. 2007;5(2 Suppl 1):13-21
  4. Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet F, Barasch A, et al. Patient‐reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. Cancer. 2008;113(10):2704-13
  5. Lalla RV, Schubert MM, Bensadoun R-J, Keefe D. Anti-inflammatory agents in the management of alimentary mucositis. Supportive Care in Cancer. 2006;14(6):558-65
  6. Shameem R, Lacouture M, Wu S. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. Cancer investigation. 2015;33(3):70-7
  7. Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Supportive Care in Cancer. 2007;15(5):491-6
  8. Ye Y, Carlsson G, Agholme MB, Karlsson-Sjöberg J, Yucel-Lindberg T, Pütsep K, et al. Pretherapeutic plasma pro-and anti-inflammatory mediators are related to high risk of oral mucositis in pediatric patients with acute leukemia: a prospective cohort study. PLoS One. 2013;8(5):e64918
  9. Stokman M, Spijkervet F, Boezen H, Schouten J, Roodenburg J, De Vries E. Preventive intervention possibilities in radiotherapy-and chemotherapy-induced oral mucositis: results of meta-analyses. Journal of dental research. 2006;85(8):690-700
  10. Walsh L. Clinical assessment and management of the oral environment in the oncology patient. Australian dental journal. 2010;55(s1):66-77
  11. Bowen JM, Gibson RJ, Keefe DM. Animal models of mucositis: implications for therapy. The journal of supportive oncology. 2011;9(5):161-8
  12. Can G, Enç N, Akkaya S. Onkoloji hemşireliğinde kanıta dayalı semptom yönetimi. Konsensus. 2007;7:64-6
  13. Harris DJ, Harriman A, Cashavelly BJ, Cathy Maxwell R. Putting evidence